IRIS
PERSONENI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.232
AS - Asia 1.511
EU - Europa 460
Continente sconosciuto - Info sul continente non disponibili 165
SA - Sud America 58
AF - Africa 28
OC - Oceania 1
Totale 4.455
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.141
SG - Singapore 648
VN - Vietnam 285
CN - Cina 267
IT - Italia 192
BD - Bangladesh 188
FR - Francia 151
SE - Svezia 45
CA - Canada 41
HK - Hong Kong 32
BR - Brasile 30
GB - Regno Unito 17
DE - Germania 16
IN - India 15
MX - Messico 13
SC - Seychelles 12
JP - Giappone 11
CO - Colombia 10
JM - Giamaica 10
CR - Costa Rica 8
IE - Irlanda 8
ID - Indonesia 7
PH - Filippine 7
TH - Thailandia 7
TR - Turchia 7
IQ - Iraq 6
UZ - Uzbekistan 6
AR - Argentina 5
EE - Estonia 5
PK - Pakistan 5
PL - Polonia 5
VE - Venezuela 5
ZA - Sudafrica 5
BE - Belgio 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
DK - Danimarca 3
EC - Ecuador 3
ES - Italia 3
KR - Corea 3
MA - Marocco 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
EG - Egitto 2
HN - Honduras 2
LB - Libano 2
MY - Malesia 2
NI - Nicaragua 2
NL - Olanda 2
PR - Porto Rico 2
PY - Paraguay 2
RU - Federazione Russa 2
AU - Australia 1
BG - Bulgaria 1
BJ - Benin 1
CH - Svizzera 1
CL - Cile 1
ET - Etiopia 1
FI - Finlandia 1
HU - Ungheria 1
JO - Giordania 1
KE - Kenya 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LT - Lituania 1
MF - Saint Martin 1
MR - Mauritania 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
SY - Repubblica araba siriana 1
Totale 4.290
Salva come PNG Salva come JPEG
Città #
San Jose 494
Council Bluffs 351
Singapore 277
Ashburn 251
Lauterbourg 143
Ho Chi Minh City 94
Boardman 79
Santa Clara 64
Hanoi 60
New York 38
Milan 37
Phoenix 36
Los Angeles 31
Rome 31
Buffalo 19
Hong Kong 18
Chicago 17
Da Nang 16
Dallas 14
Atlanta 11
Naples 11
Philadelphia 10
Beijing 8
Haiphong 8
Montreal 8
Dublin 7
Kingston 7
Thomasville 7
Toronto 7
Chandler 6
Charlotte 6
Denver 6
Frankfurt am Main 6
Las Vegas 6
Pasadena 6
Tokyo 6
Alexandria 5
Bologna 5
Hải Dương 5
Jakarta 5
Johannesburg 5
Mexico City 5
Orem 5
Queens 5
San Antonio 5
San José 5
The Bronx 5
Toms River 5
Brasília 4
Can Tho 4
Catania 4
Champaign 4
Detroit 4
London 4
Miami 4
Nashua 4
Nuremberg 4
Orlando 4
Pageland 4
Querétaro 4
Sacramento 4
San Francisco 4
San Salvador 4
Seattle 4
Shanghai 4
Slatington 4
São Paulo 4
Tashkent 4
Washington 4
Abbeville 3
Bangkok 3
Bari 3
Bogotá 3
Brooklyn 3
Charleston 3
Chennai 3
Dhaka 3
Easton 3
Fayetteville 3
Genoa 3
Houston 3
Istanbul 3
Joliet 3
Milwaukee 3
Modena 3
Mumbai 3
Newark 3
Palermo 3
Providence 3
Reggio Calabria 3
Shenzhen 3
St Louis 3
Thanh Mỹ Tây 3
Turin 3
Tân Tiến 3
Verona 3
Vicenza 3
Virginia Beach 3
Wichita 3
'Ewa Beach 2
Totale 2.432
Salva come PNG Salva come JPEG
Nome #
KRAS mutation in lung metastases from colorectal cancer: Prognostic implications 90
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression : a Phase II Study 83
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study 80
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 76
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma 72
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 58
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 52
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 46
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 45
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 44
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 44
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 41
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 41
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 41
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer : the VanGogh study 40
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 40
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 40
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 39
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma 38
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 38
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 37
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 37
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 37
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients 37
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 36
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 36
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 36
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 36
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 36
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 36
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 35
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 35
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 34
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 34
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer 34
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 33
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 33
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 32
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 32
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 32
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 32
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study 31
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 31
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 31
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 31
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 31
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 31
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 30
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 30
Which choice of therapy when many are available? - Current systemic therapies for advanced hepatocellular carcinoma 30
Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 29
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 29
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 29
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 29
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 28
Regorafenib for the treatment of unresectable hepatocellular carcinoma 28
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 28
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 28
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 28
Biomarkers in Hepatocellular Carcinoma-Letter 28
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial 28
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 27
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 27
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 27
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 27
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade 26
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes 26
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 26
Tivantinib for hepatocellular carcinoma 26
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 26
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 26
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 26
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 26
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 26
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 26
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 26
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 26
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer : a safe and effective approach 25
COVID-19 and liver cancer clinical trials: not everything is lost 25
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 25
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma 25
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 24
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 24
Tivantinib : a new promising mesenchymal–epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 24
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 24
Cabozantinib for the treatment of hepatocellular carcinoma 24
Standardisation of EGFR FISH in colorectal cancer: Results of an international interlaboratory reproducibility ring study 23
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? 23
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 23
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 23
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 23
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells 23
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 23
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 23
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy 22
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 22
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials 22
OncoAlert round table discussions: The global COVID-19 experience 22
Reply to Y. Pointreau et al 22
Hepatocellular Carcinoma : A Global Disease in Need of Individualized Treatment Strategies 21
Totale 3.321
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.636
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.636
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223 0 0 0 1 0 0 0 0 1 0 0 1
2022/202321 3 2 0 1 4 2 1 0 8 0 0 0
2023/20243 0 2 0 0 0 0 0 1 0 0 0 0
2024/202522 1 2 2 0 1 6 1 0 3 1 0 5
2025/20262.752 3 7 4 3 319 364 570 275 484 245 328 150
2026/20271.653 573 367 360 353 0 0 0 0 0 0 0 0
Totale 4.455